

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

December 06, 2005

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): December 1, 2005  
IntraBiotics Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

**0-29993**

**94-3200380**

(State or other jurisdiction  
of incorporation)

(Commission File Num

ber) (IRS Employer Identification  
No.)

**1009 Oak Hill Road, Suite 201  
Lafayette, CA 94549**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(925) 906-5331**  
**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02(b). Departure of Directors or Principal Officers:**

On December 1, 2005, Mr. Mark L. Perry provided IntraBiotics Pharmaceuticals, Inc. (the Company ) with a notice of resignation from the Company s Board of Directors and all committees of the Board effective as of such date.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**INTRABIOTICS PHARMACEUTICALS,  
INC.**

Date: December 6, 2005

By: /s/ Denis Hickey  
Denis Hickey  
Chief Executive Officer and Chief  
Financial Officer